BIOMAT Database Logo BIOMAT Database Logo

Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus-infected children. 1999

M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Zidovudine therapy in thrombocytopenic human immunodeficiency virus-infected children.
November 1991, The Pediatric infectious disease journal,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
February 1997, The Journal of pediatrics,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
December 2002, Antimicrobial agents and chemotherapy,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
July 1993, The Journal of pediatrics,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
September 2001, The Journal of infectious diseases,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy.
July 1991, The Journal of pediatrics,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
November 2000, Antimicrobial agents and chemotherapy,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
August 2000, The Journal of infectious diseases,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
December 2002, Antiviral therapy,
M Funk, and R Linde, and H J Braner, and B Groeschel, and B Kornhuber, and W Kreuz
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
January 2001, Pediatrics,
Copied contents to your clipboard!